About: Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Latest price: $5.11 (-7.26%)
PTN NASDAQ Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc. Common Stock share price
PTN price activity
Last Price
$5.110
Change (24hr)
-0.40 USD (7.26%)
Volume
126.57K
Volume (4w avg)
-
Open
$5.44
Day Range
$4.92 - $5.89
Previous Close
$5.51
Last Trade
23 Oct, 8:03 pm GMT+0
Delayed
23 Oct, 8:03 pm GMT+0
PTN price performance
Delayed
23 Oct, 8:03 pm GMT+0
PTN Market Signals